| 5 | 1/1 | 返回列表 |
| 查看: 2288 | 回復(fù): 11 | |||||
| 當(dāng)前只顯示滿足指定條件的回帖,點(diǎn)擊這里查看本話題的所有回帖 | |||||
[交流]
GSK被調(diào)查,會對醫(yī)藥行業(yè)各個(gè)產(chǎn)業(yè)鏈產(chǎn)生什么影響 已有11人參與
|
|||||
| 大家都來深入淺出的分析一下 |
新藥研發(fā)必備資料 | 行業(yè)動態(tài) |
金蟲 (小有名氣)
銀蟲 (小有名氣)
|
柳葉刀文章,轉(zhuǎn)自丁香園,分析GSK事件,說中國醫(yī)患問題可能與醫(yī)生和某些藥企的不健康關(guān)系有關(guān),請看下文: Doctors and pharma in China The Lancet Doctor—patient relationships in China are in crisis. Doctors have been injured or even killed by patients at work. One of the major drivers might be the unhealthy and unethical relations between many doctors and some drug companies. On July 8, GlaxoSmithKline (GSK) said that they were investigating allegations that its staff had improperly used cash and other incentives to encourage the prescription of onabotulinumtoxin A (Botox) in China. The company added that “inquiries to date have found no evidence of bribery or corruption in relation to our sales and marketing of therapeutic Botox in China.” The Lancet has no evidence to suggest that the allegations against GSK in China are true. However, some observers claim that bribing doctors to boost drug prescriptions by some drug companies is an open secret, and that this alleged practice has compromised the public's trust in doctors. The varieties of unethical relationships that exist between some doctors and some of the drug companies in China are said to range from cash kickbacks, lavish gifts or entertainment, ghost writing services, sponsored supplements in journals, and all-expenses-paid trips. There is real concern that doctors' prescriptions are therefore not based solely on patient need and clinical evidence, but may be biased by commercial interests. The perceived unethical association between physicians and industry in China is worrying, because it inevitably harms patients as well as doctors. It damages the doctor—patient relationship and, ultimately, China's whole health system. The GSK China allegations, although unproven, have clearly rung an alarm bell for China's regulatory authorities to ensure the drug industry promotes products in a responsible, ethical, and professional way. Chinese doctors should rely on evidence-based clinical guidelines to inform their practice, and are in urgent need of guidance on their collaborations with the drug industry in various areas such as patient care, professional education, and research. Furthermore, training for doctors in China on managing their relationships ethically with the drug industry and other organisations should start at medical school and be part of continuing professional education. |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 工科材料085601 279求調(diào)劑 +6 | 困于星晨 2026-03-17 | 8/400 |
|
|---|---|---|---|---|
|
[考研]
|
.6lL 2026-03-18 | 7/350 |
|
|
[考研] 材料專碩英一數(shù)二306 +6 | z1z2z3879 2026-03-18 | 6/300 |
|
|
[考研] 一志愿蘇州大學(xué)材料求調(diào)劑,總分315(英一) +3 | sbdksD 2026-03-19 | 3/150 |
|
|
[考研]
|
不想起名字112 2026-03-19 | 3/150 |
|
|
[考研] 一志愿天津大學(xué)化學(xué)工藝專業(yè)(081702)315分求調(diào)劑 +11 | yangfz 2026-03-17 | 11/550 |
|
|
[考研] 材料與化工求調(diào)劑 +7 | 為學(xué)666 2026-03-16 | 7/350 |
|
|
[考研] 化學(xué)求調(diào)劑 +3 | 臨澤境llllll 2026-03-17 | 4/200 |
|
|
[考研] 332求調(diào)劑 +3 | ydfyh 2026-03-17 | 3/150 |
|
|
[考研] 一志愿華中科技大學(xué),080502,354分求調(diào)劑 +4 | 守候夕陽CF 2026-03-18 | 4/200 |
|
|
[考研] 【同濟(jì)軟件】軟件(085405)考研求調(diào)劑 +3 | 2026eternal 2026-03-18 | 3/150 |
|
|
[考研] 311求調(diào)劑 +6 | 26研0 2026-03-15 | 6/300 |
|
|
[考研] 312求調(diào)劑 +8 | 陌宸希 2026-03-16 | 9/450 |
|
|
[考研] 304求調(diào)劑 +12 | 小熊joy 2026-03-14 | 13/650 |
|
|
[基金申請] 被我言中:新模板不強(qiáng)調(diào)格式了,假專家開始管格式了 +4 | beefly 2026-03-14 | 4/200 |
|
|
[論文投稿] 有沒有大佬發(fā)小論文能帶我個(gè)二作 +3 | 增銳漏人 2026-03-17 | 4/200 |
|
|
[考研] 一志愿,福州大學(xué)材料專碩339分求調(diào)劑 +3 | 木子momo青爭 2026-03-15 | 3/150 |
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學(xué)獎覬?/a> 2026-03-15 | 7/350 |
|
|
[考研] 求老師收留調(diào)劑 +4 | jiang姜66 2026-03-14 | 5/250 |
|
|
[碩博家園] 085600 260分求調(diào)劑 +3 | 天空還下雨么 2026-03-13 | 5/250 |
|